Svmuu News: Cathie Wood posted on X, stating that according to ARK Invest’s research, the most far-reaching application of AI will be in healthcare. Deregulation is accelerating this transformation in the healthcare sector. The science of evaluating drug efficacy has made tremendous strides, with R&D projects gathering evidence across multiple dimensions—including mechanisms of action, biomarker effects, and intermediate endpoints. This confirmatory evidence, ranging from mechanistic data to real-world evidence, can replace the second pivotal trial. Historically, there has been greater regulatory flexibility in the fields of rare diseases and oncology. It is anticipated that this shift from two trials to one will have the greatest impact in areas of common diseases such as cardiovascular and respiratory conditions, with each project expected to save up to $350 million in costs and shorten the R&D cycle by several years.